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Introduction
Worldwide hurricane of 92 million cases of chlamydia trachomatis 
infection was estimated by WHO in 2001 [1]. High prevalence of sexually 
transmitted infections in Europe [2] and in the United States [3] would 
recommend it as a leading cause of cervicitis, pelvic inflammatory 
disease (PID), Salpingitis, ectopic pregnancy and infertility [4]. It is too 
prevalent in developing countries [5]. Chlamydia as a mucosotropic 
[6] intracellular bacterium is a facilitating factor of HIV transmission 
and also is a cofactor of HPV-induced cervical neoplasia [7]. Thus, 
administration of vaccine absolutely is necessary to save $2 billion per 
year [8]. The perfect protection model is focused on subunit vaccine 
using major outer membrane protein (MOMP) [9]. Among different 
proteins of chlamydial, MOMP as an immunodominant, Surface-
Exposed antigen is mostly investigated as the best potentially candidate 
for a subunit vaccine. MOMP is greatly antigenic which known as a 
porin and the representative of Peptidoglycan layer [10]. In this attempt, 
beside molecular gene cloning and protein expression methods in 
prokaryotic system, antigenic domain of MOMP were predicted using 
prediction tools. Our suggestion is that MOMP160-376 which named 
rMOMP217 during this paper would be a new member of potentially 
vaccine candidate among collection investigated during so many 
years. But undoubtedly this present study needs further experimental 
works to develop an effective vaccine instead of both therapeutic and 
prophylactic proceedings.
Material and Methods
Bacterial strains And Vector
Chlamydia trachomatis strain L1/440, E.coli DH5α and E.coli BL21 
(DE3) for cloning and Expression experiments were obtained from 
Avicenna Research Institute Microbial Bank. pET28b expression vector 
was also provided from Avicenna Research Institute.
PCR Amplification
MOMP217 was amplified with Taq DNA polymerase (Vivantis). 
Primers were designed with BamHI and HindIII restriction sites 
at the 5` of forward and reverse, respectively. Primers designed to 
amplify MOMP217 gene fragment (corresponding to nucleotides 
160-376) was according to information retrived from NCBI data 
Bank. The forward primer incorporated a BamHI restriction enzyme 
site (bold) and a start codon (underlined) with the sequence, 
5’-GTTGGGGATCCTGGAGATAATGAAAAT-3’ and the reverse 
primer incorporated a HindIII site (bold) and a stop codon (underlined), 
5’-ACTCTAAGCTTCTCAACTGTAACTGCGTATTT-3’ (Figure 1). 
In brief Total volume of each reaction was 25 µl which consisted of 
1mM of each primer, 10X PCR buffer 0.6 mM dNTPs, 5 mM MgCl2, 
1.0 U Taq polymerase (Vivantis) and 1 µl of the template DNA. PCR 
condition were as follow: initial denaturing at 95°C for 5 min, 40 cycles 
including 30s at 95°C, 30 s at 53.5°C, 1/30 s at 72°C and a final extension 
at 72°C for 5 min. Hence, the expected 674 bp band was purified directly 
with clean-up process using Qiagen purification kit buffers. 
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Abstract
Administration of Prophylactic vaccines still is the cutting-edge of prevention, control and elimination of infections. 
Among the common causes of sexually transmitted diseases, chlamydia trachomatis is an important socioeconomic 
burden worldwide which impairs human genital tract function, resulting in severe complications like urethritis, pelvic 
inflammatory disease (PID), getting ease of HIV transmission, playing cofactor role in human papilloma virus (HPV)-
induced cervical neoplasia, and unfortunately infertility. Because of all difficulties, vaccination is considered to be 
the most economical and reliable way to escape from unrestrained exacerbation states of infection than any other 
prevalence program. But despite much advancement in the field of veterinary, the dream has yet to be realized. 
Among a number of potential candidates, the major outer membrane protein (MOMP) is a vanguard of subunit 
vaccines. In this attempt, MOMP217 gene fragment cloned in PET28b+ and expressed in E.coli. The protein 
expression confirmed by SDS-PAGE. These findings demonstrate that, considering the antigenicity prediction 
and due to the existence of potential epitopic region, rMOMP217 could be a potential capable peptide which can 
represent as an alternative to whole MOMP.
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Bioinformatic
Amino acid sequence of MOMP in FASTA format was elicited from 
protein data bank. There is no available evidence from 3D structure of 
MOMP in PDB (Protein Data Bank). Prediction of antigenic domain of 
MOMP was performed by Kolaskar and Tonaonkar method.
Secondary structure of MOMP serovar L1 was predicted by GOR 
(Garnier-Osguthorpe-Robson). Multiple Alignments between serovar 
E, L1, L2 and L3 for detecting the conserved common regions was 
performed by European Bioinformatics Institute website.
Cloning of PET-MOMP217
PCR was performed to amplify the MOMP217 containing epitopic 
regions with specific primers. Qiagen gel extraction kit (Qiagen, Hilden, 
Germany) was used to purify PCR amplified product and plasmid 
DNA. Purified plasmid and amplified insert were double digested with 
BamHI and HindIII (Fermentase). The digested products were purified 
and ligated into linearised and purified vector withT4 DNA ligase 
enzyme(Fermentase), then ligation mixture were transformed into 
E.coli DH5α cloning host. As well, Recombinant clones were confirmed 
by colony PCR and double digestion. The confirmed purified DH5α/
pET- MOMP217 positive colony were transformed and cloned into 
E.coli BL21 (DE3) expression host and used for protein expression 
purpose with IPTG.
Protein expression
E.coli BL2 (DE3) with T7 promoter, harboring the PET- MOMP217 
(24kDa) positive colony were grown in 100 ml LB broth at 37°C 
including 100 µg/ml kanamycin (Sigma) to achieve an optical density 
(OD) of 0.7 (stationary growth phase) at 600 nm at this time, 1 mM 
isopropyl-ß-D-thiogalactoside (IPTG; Invitrogen) were added to 50 ml 
LB broth and the other same amount were considered as uninduced 
(-IPTG) control. Incubation was continued at 37°C. The samples from 
induced and uninduced culture were collected within 2, 4, 6 hours 
and overnight after induction. Incubation temperature in the case of 
overnight was reduced to 25°C. Samples were accumulated, centrifuged 
at 6000 rpm for 5 min. Harvested cells were resuspending with 2x 
loading protein buffer containing 2-ME, boiled and subjected to SDS-
PAGE analysis. Total protein expression trend were evaluated by 10% 
SDS-PAGE stained with Comassie Brilliant Blue. SDS-PAGE were 
shown to have one band corresponded to recombinant protein which 
were termed as rMOMP217 (Table 1).
Result
Recombinant plasmid
 The MOMP217=truncated omp1, was amplified by polymerase 
chain reaction. Then, digested insert and linearised plasmid associated, 
pET28b, were ligated and cloned into E.coli DH5α cloning host resulting 
DH5α /PET-MOMP217 Recombinant clones were transferred into 
BL21 expression host concluding BL21/PET-. MOMP217.
Expression of recombinant protein
The expression of rMOMP217 was induced by adding IPTG in 1 mM 
final concentration. The mass of rMOMP in induced and uninduced 
culture were evaluated by SDS-PAGE. The 24 kDa molecular mass was 
not noticeable in uninduced cells whereas was recognizable within 2, 4, 
6 hours and over night after induction (Figure 2).
Bioinformatic and antigenicity prediction research
The multiple alignments of the MOMP sequences by clustalw2 
helped to determine conserved common regions between L1, L2, L3 
and E serovars respectively. This experiment showed high similarity in 
conserved domain. C.Trachomatis serovar L1 was as a template in the 
entire of study. Crucial attributes of antigenic epitopes are flexibility 
and hydrophilicity; secondary structure prediction by GOR shown 
flexible region like random coil. Antigenicity prediction by Kolaskar 
and Tonaonkar method demonstrated antigenic domain which were 
shown by plus (Table 1).
Discussion
Is Vaccinology almost forgotten? To be frank, neither screening 
programs nor controlling trials are able to overcome the threats about 
reproductive issue. Whereas, Vaccination is unequivocally pivotal to 
tackle the diseases. It has also been one of the most important health 
advances in history. Approximately, 92 million young adults suffer from 
this considerable public health concern [11]. Therefore, vaccination 
is an important strategy not only for chlamydiosis but also for other 
STIs [12]. Complications like ectopic pregnancy, pelvic inflammatory 
disease (PID) and infertility suggest more attention on this turbulent, 
silent and unfortunately neglected disease. Particularly, for women lack 
of a protective vaccine has existed as the health problem. Data were 
gathered from multiple sources at various time points noticed the 
importance of MOMP as a subunit vaccine candidate. MOMP, encoded 
by OmpA gene, has been the antigen tested in many investigational 
studies and known as a primary of vaccine development [13]. MOMP is 
a promising, immunodominant and Surface-Exposed antigen which is 
able to stimulate both humoral and cellular immunity [14]. To date, no 
vaccine licensed for human use is available. This view is supported by A. 
Feher who writes “a prophylactic vaccine has long been sought against 
C.trachomatis but has yet to be obtained” [15]. Moreover, despite 
advancement in the field of veterinary currently there is, however, no 
human protective vaccine [16]. Also, orientations of newly strategies in 
“OMICS” technology like vaccinomics are trying to produce an effective 
vaccine that would serve immunity against genital chlamydiosis [17]. 
In the history of vaccine development, single or multisubunit vaccine 
is the major focus of chlamydial Vaccinology [18]. Harmful effect of 
whole organism, as well reverting to a virulent form has shifted in Table 1: Prediction of Antigenic Region of  Chlamydia Trachomatis Serovar L1.
            .   10    .   20    .   30    .   40    .   50
        MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMIDGILWEGFGGDPCDP
epitope    +++++++++++++++++++++++++ +++++++++      ++++++
            .   60    .   70    .   80    .   90    .  100
        CTTWCDAISMRMGYYGDFVFDRVLQTDVNKEFQMGAKPTATTG-
NAAAPST
epitope ++++++++       ++++++++++++                       
            .  110    .  120    .  130    .  140    .  150
        CTARENPAYGRHMQDAEMFTNAAYMALNIWDRFDVFCTLGATSGYLKGNS
epitope                                +++++++++          
            .  160    .  170    .  180    .  190    .  200
        ASFNLVGLFGDNENQSTVKKDAVPNMSFDQSVVELYTDTTFAWSVGARAA
epitope   +++++++                   ++++++++     +++++++++
            .  210    .  220    .  230    .  240    .  250
        LWECGCATLGASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGKEFPLD
epitope ++++++++++++++++++++++++++++++++       +++++++    
            .  260    .  270    .  280    .  290    .  300
        LTAGTDAATGTKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDAD
epitope                     ++++++++++     ++++++++       
            .  310    .  320    .  330    .  340    .  350
        TIRIAQPKLATAIFDTTTLNPTIAGAGEVKANAEGQLGDTMQIVSLQLNK
epitope  ++++++++++++                           ++++++++  
            .  360    .  370    .  380    .  390
        MKSRKSCGIAVGTTIVDADKYAVTVETRLIDERAAHVNAQFRF
epitope     ++++++++++++++++++++++++     +++++++   
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subunit vaccine toward the first generation vaccine [19]. Despite the 
necessity of additional factors like delivery system and adjuvant [15], 
for both immunocompromised patients and pregnant women who 
can’t safely take live vaccinations it would be an effective alternative. 
Human subunit vaccines are currently available against pneumococci, 
meningococci, Haemophilus inﬂuenza, and hepatitis B and inﬂuenza 
virus [20]. But to improve the insight into designing an effective vaccine, 
it is crucial to get concrete knowledge about immunological aspect of 
this infection, besides the role of both humoral and cellular immunity 
as two arms of immune system. Indeed, successful protection requires 
the stimulation of T-cell in addition to antibody responses [21]. In the 
current study, we were being able to predict precisely antigenic region 
through bioinformatic and antigenicity prediction tools to produce a 
truncated protein instead of a full-length. Truncated protein’s nature 
reflecting this reality that short segment derive from protein make it 
more appropriate to fuse with other genes to construct a fusion protein. 
Not long ago, novel B-cell epitopes containing mostly conserved 
region and high antigenicity. They were MOMP73-81, MOMP161-175, 
MOMP217-225, MOMP261-270 and MOMP377-386 in the N-terminal 
region. Surprisingly MOMP377-386 was the strongest epitope followed 
by challenging in mice [22]. It is undoubtedly true that B-cell responses 
are essential. However, T-cell derived immune response and peptides 
including T-cell epitopes due to the significant role of CTL and Th 
during infection are absolutely important. Also, the small fragment of 
MOMP containing T-cell epitope, rMOMP278, was able to elicit both 
systemic, mucosal and a balanced Th1/Th2 immune responses [23]. It 
would be a valuable candidate in order to formulate a T-cell vaccine. 
Regarding to our research, MOMP217 were expressed as 6xHis-tagged 
protein. SDS-PAGE analysis confirmed desired expression condition 
and showed that this expressed protein could readily purify with Ni-
NTA affinity chromatography. To construct a recombinant plasmid, 
pET28b were used as an expression vector. This approach has an 
attractive feature that during protein purification, pET28b needs 
Thrombin to remove fusion tag, while other like pET32a resulting 
Trx-His-tag needs one more expensive enzyme like Enterokinase to 
remove the fusion tag. The mentioned fusion tag make an intervention 
in protein activity; obviously whenever total protein inject to animals, 
antibodies would elicit against both targeted protein and fusion tag. 
Thus, purification of protein in prokaryotic expression system with 
purification affinity tag like 6-His tag is easier than other vectors. It has 
a little influence on protein function because 6-His belongs to the insert 
amino acids with poor immunogenicity and is easy to remove [24]. The 
highest throughput of protein expression obtained at 30°Cto produce 
recombinant Hemoglobin II from Lucina pectinata [25]. A recent study 
optimized the convenient condition for mature PsaA expression in 
Escherichia coli for about 16 h at 25°C with 0.1 mM IPTG in Terrific 
Broth medium [26]. Taken together, these findings have tended to focus 
on optimal condition for protein expression. Growth in 37°C resulted 
in accumulation of inclusion body while incubation in 25°C produce 
more soluble form of protein, in fact this temperature helps the bacteria 
to consume all energy toward protein biosynthesis and not cell division. 
It may be explained by the fact that night expression without any needs 
to follow is the best system to increase the yield of protein expression. 
To our knowledge, the truncated protein in this study is a first report 
and contains some important epitopic region. The result for SDS-PAGE 
demonstrate that our constructed prokaryotic system PET28b-BL21 
MOMP217 (DE3) produce target recombinant protein. The current 
investigation was limited by economical problem as a big issue in 
developing countries. Accordingly, more research on this topic needs 
to be attempted before introducing as a vaccine candidate. Therefore, 
further empirical researches on the current study are recommended. 
Since, massive improvement is needed in human vaccine, recent 
developments have heightened a convenient adjuvant and delivery 
system for a human vaccine. The vaccine needs to promote two CMI 
and antibody response, CAF01 is an adjuvant that is appropriate to 
enter human clinical trials in future [27]. CPG and Montanide are 
two other adjuvants that are now in clinical trials [28,29]. In addition, 
Novel delivery systems, including Vibrio cholerae ghosts and cationic 
liposomes, may have the potential to elicit protective responses against 
chlamydial genital infection when used in conjunction with appropriate 
antigens [30]. To summarize, if the debate is to move forward, a better 
understanding of more delivery systems and eligible adjuvant needs 
to be developed. As well, better technological possibilities combined 
with proteomics, immunology and immunoinformatic, allow for new 
vaccination strategies (Figures 1 and 2).
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